Publicação: β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats
Carregando...
Arquivos
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Tipo
Artigo
Direito de acesso
Acesso aberto
Resumo
Background: There is increasing interest in non-pharmacological control of cholesterol and triglyceride levels in the plasma and diet-drug association represent an important area of studies. The objective of this study was to observe the hypocholesterolemic effect of soybean β-conglycinin (7S protein) alone and combined with fenofibrate and rosuvastatin, two hypolipidemic drugs. Methods. The protein and drugs were administered orally once a day to rats and the effects were evaluated after 28 days. Wistar rats were divided into six groups (n = 9): hypercholesterolemic diet (HC), HC+7S protein (300 mg.kg-1 day-1) (HC-7S), HC+fenofibrate (30 mg.kg-1 day-1)(HC-FF), HC+rosuvastatin (10 mg.kg-1 day-1)(HC-RO), HC+7S+fenofibrate (HC-7S-FF) and HC+7S+rosuvastatin (HC-7S-RO). Results: Animals in HC-7S, HC-FF and HC-RO exhibited reductions of 22.9, 35.8 and 18.8% in total plasma cholesterol, respectively. In HC-7S-FF, animals did not show significant alteration of the level in HC+FF while the group HC-7S-RO showed a negative effect in comparison with groups taking only protein (HC-7S) or drug (HC-RO). The administration of the protein, fenofibrate and rosuvastatin alone caused increases in the plasma HDL-C of the animals, while the protein-drug combinations led to an increase compared to HC-FF and HC-RO. The plasma concentration of triacylgycerides was significantly reduced in the groups without association, while HC-7S-FF showed no alteration and HC-7S-RO a little reduction. Conclusion: The results of our study indicate that conglycinin has effects comparable to fenofibrate and rosuvastatin on the control of plasma cholesterol, HDL-C and triacylglycerides, when given to hypercholesterolemic rats, and suggests that the association of this protein with rosuvastatin alters the action of drug in the homeostasis of cholesterol. © 2012 Ferreira et al; licensee BioMed Central Ltd.
Descrição
Palavras-chave
β-conglycinin, cholesterol-lowering drugs, hypercholesterolemic diet, rats., beta conglycinin, fenofibrate, high density lipoprotein cholesterol, rosuvastatin, soybean protein, triacylglycerol, unclassified drug, beta conglycinin protein, Glycine max, beta-conglycinin protein, Glycine max, cholesterol, fluorobenzene, globulin, hypocholesterolemic agent, plant antigen, pyrimidine derivative, seed storage protein, sulfonamide, animal experiment, animal model, cholesterol blood level, controlled study, diet, hypercholesterolemia, hypocholesterolemia, male, nonhuman, rat, triacylglycerol blood level, animal, blood, drug combination, drug effect, drug potentiation, heart, heart muscle, isolation and purification, lipid diet, liver, metabolism, organ size, pathology, protein intake, soybean, Wistar rat, Animalia, Glycine max, Rattus, Rattus norvegicus, Animals, Anticholesteremic Agents, Antigens, Plant, Cholesterol, Diet, High-Fat, Dietary Proteins, Drug Combinations, Drug Synergism, Fenofibrate, Fluorobenzenes, Globulins, Heart, Hypercholesterolemia, Liver, Male, Myocardium, Organ Size, Pyrimidines, Rats, Rats, Wistar, Seed Storage Proteins, Soybean Proteins, Soybeans, Sulfonamides, Triglycerides
Idioma
Inglês
Como citar
Lipids in Health and Disease, v. 11.
